CDKN2A and glioblastoma: To address the above questions, this retrospective study aims to leverage our large institutional data to evaluate the clinical outcomes of mGBM as compared to hGBM and to elucidate the prognostic impact of TERT mutation, EGFR amplification, and CDKN2A/B deletion on IDH-wildtype GBM.